158 related articles for article (PubMed ID: 37689718)
1. High throughput compound screening in neuronal cells identifies statins as activators of ataxin 3 expression.
Stahl F; Schmitt I; Denner P; de Boni L; Wüllner U; Breuer P
Sci Rep; 2023 Sep; 13(1):14911. PubMed ID: 37689718
[TBL] [Abstract][Full Text] [Related]
2. Spinocerebellar Ataxia Type 3 Pathophysiology-Implications for Translational Research and Clinical Studies.
Stahl F; Evert BO; Han X; Breuer P; Wüllner U
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612794
[TBL] [Abstract][Full Text] [Related]
3. Druggable genome screen identifies new regulators of the abundance and toxicity of ATXN3, the Spinocerebellar Ataxia type 3 disease protein.
Ashraf NS; Sutton JR; Yang Y; Ranxhi B; Libohova K; Shaw ED; Barget AJ; Todi SV; Paulson HL; Costa MDC
Neurobiol Dis; 2020 Apr; 137():104697. PubMed ID: 31783119
[TBL] [Abstract][Full Text] [Related]
4. Comparison of spinocerebellar ataxia type 3 mouse models identifies early gain-of-function, cell-autonomous transcriptional changes in oligodendrocytes.
Ramani B; Panwar B; Moore LR; Wang B; Huang R; Guan Y; Paulson HL
Hum Mol Genet; 2017 Sep; 26(17):3362-3374. PubMed ID: 28854700
[TBL] [Abstract][Full Text] [Related]
5. CRISPR/Cas9-Targeted Deletion of Polyglutamine in Spinocerebellar Ataxia Type 3-Derived Induced Pluripotent Stem Cells.
Ouyang S; Xie Y; Xiong Z; Yang Y; Xian Y; Ou Z; Song B; Chen Y; Xie Y; Li H; Sun X
Stem Cells Dev; 2018 Jun; 27(11):756-770. PubMed ID: 29661116
[TBL] [Abstract][Full Text] [Related]
6. The stress granule protein G3BP1 alleviates spinocerebellar ataxia-associated deficits.
Koppenol R; Conceição A; Afonso IT; Afonso-Reis R; Costa RG; Tomé S; Teixeira D; da Silva JP; Côdesso JM; Brito DVC; Mendonça L; Marcelo A; Pereira de Almeida L; Matos CA; Nóbrega C
Brain; 2023 Jun; 146(6):2346-2363. PubMed ID: 36511898
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of miR-25 and miR-181 Family Members Correlates with Reduced Expression of ATXN3 in Lymphocytes from SCA3 Patients.
Krauss S; Nalavade R; Weber S; Carter K; Evert BO
Microrna; 2019; 8(1):76-85. PubMed ID: 30147021
[TBL] [Abstract][Full Text] [Related]
8. A fine balance between Prpf19 and Exoc7 in achieving degradation of aggregated protein and suppression of cell death in spinocerebellar ataxia type 3.
Chen ZS; Huang X; Talbot K; Chan HYE
Cell Death Dis; 2021 Feb; 12(2):136. PubMed ID: 33542212
[TBL] [Abstract][Full Text] [Related]
9. Toward allele-specific targeting therapy and pharmacodynamic marker for spinocerebellar ataxia type 3.
Prudencio M; Garcia-Moreno H; Jansen-West KR; Al-Shaikh RH; Gendron TF; Heckman MG; Spiegel MR; Carlomagno Y; Daughrity LM; Song Y; Dunmore JA; Byron N; Oskarsson B; Nicholson KA; Staff NP; Gorcenco S; Puschmann A; Lemos J; Januário C; LeDoux MS; Friedman JH; Polke J; Labrum R; Shakkottai V; McLoughlin HS; Paulson HL; Konno T; Onodera O; Ikeuchi T; Tada M; Kakita A; Fryer JD; Karremo C; Gomes I; Caviness JN; Pittelkow MR; Aasly J; Pfeiffer RF; Veerappan V; Eggenberger ER; Freeman WD; Huang JF; Uitti RJ; Wierenga KJ; Marin Collazo IV; Tipton PW; van Gerpen JA; van Blitterswijk M; Bu G; Wszolek ZK; Giunti P; Petrucelli L
Sci Transl Med; 2020 Oct; 12(566):. PubMed ID: 33087504
[TBL] [Abstract][Full Text] [Related]
10. Urine levels of the polyglutamine ataxin-3 protein are elevated in patients with spinocerebellar ataxia type 3.
Koike Y; Jansen-West KR; Hanna Al-Shaikh R; Carlomagno Y; Song Y; Dunmore JA; LeDoux MS; Friedman JH; Pena AB; Uitti RJ; Zaremba J; van Gerpen JA; Pfeiffer RF; Veerappan V; Aiba I; Hashimoto R; Giles SS; Shah JS; Tipton PW; Huang JF; Wierenga KJ; Aasly J; Fryer JD; Petrucelli L; Wszolek ZK; Prudencio M
Parkinsonism Relat Disord; 2021 Aug; 89():151-154. PubMed ID: 34303201
[TBL] [Abstract][Full Text] [Related]
11. RAN Translation of the Expanded CAG Repeats in the SCA3 Disease Context.
Jazurek-Ciesiolka M; Ciesiolka A; Komur AA; Urbanek-Trzeciak MO; Krzyzosiak WJ; Fiszer A
J Mol Biol; 2020 Dec; 432(24):166699. PubMed ID: 33157084
[TBL] [Abstract][Full Text] [Related]
12. Loss of the Spinocerebellar Ataxia type 3 disease protein ATXN3 alters transcription of multiple signal transduction pathways.
Zeng L; Zhang D; McLoughlin HS; Zalon AJ; Aravind L; Paulson HL
PLoS One; 2018; 13(9):e0204438. PubMed ID: 30231063
[TBL] [Abstract][Full Text] [Related]
13. The potential of indole and a synthetic derivative for polyQ aggregation reduction by enhancement of the chaperone and autophagy systems.
Lin CH; Wu YR; Kung PJ; Chen WL; Lee LC; Lin TH; Chao CY; Chen CM; Chang KH; Janreddy D; Lee-Chen GJ; Yao CF
ACS Chem Neurosci; 2014 Oct; 5(10):1063-74. PubMed ID: 25197952
[TBL] [Abstract][Full Text] [Related]
14. miRNA-Mediated Knockdown of ATXN3 Alleviates Molecular Disease Hallmarks in a Mouse Model for Spinocerebellar Ataxia Type 3.
Nobre RJ; Lobo DD; Henriques C; Duarte SP; Lopes SM; Silva AC; Lopes MM; Mariet F; Schwarz LK; Baatje MS; Ferreira V; Vallès A; Pereira de Almeida L; Evers MM; Toonen LJA
Nucleic Acid Ther; 2022 Jun; 32(3):194-205. PubMed ID: 34878314
[TBL] [Abstract][Full Text] [Related]
15. Ubiquitin-binding site 1 of pathogenic ataxin-3 regulates its toxicity in
Prifti MV; Libohova K; Harris AL; Tsou WL; Todi SV
Front Neurosci; 2022; 16():1112688. PubMed ID: 36733922
[TBL] [Abstract][Full Text] [Related]
16. Lysine 117 on ataxin-3 modulates toxicity in
Blount JR; Patel NC; Libohova K; Harris AL; Tsou WL; Sujkowski A; Todi SV
bioRxiv; 2023 Jun; ():. PubMed ID: 37398109
[TBL] [Abstract][Full Text] [Related]
17. CRISPR/Cas9 mediated gene correction ameliorates abnormal phenotypes in spinocerebellar ataxia type 3 patient-derived induced pluripotent stem cells.
He L; Wang S; Peng L; Zhao H; Li S; Han X; Habimana JD; Chen Z; Wang C; Peng Y; Peng H; Xie Y; Lei L; Deng Q; Wan L; Wan N; Yuan H; Gong Y; Zou G; Li Z; Tang B; Jiang H
Transl Psychiatry; 2021 Sep; 11(1):479. PubMed ID: 34535635
[TBL] [Abstract][Full Text] [Related]
18. Caffeic acid and resveratrol ameliorate cellular damage in cell and Drosophila models of spinocerebellar ataxia type 3 through upregulation of Nrf2 pathway.
Wu YL; Chang JC; Lin WY; Li CC; Hsieh M; Chen HW; Wang TS; Wu WT; Liu CS; Liu KL
Free Radic Biol Med; 2018 Feb; 115():309-317. PubMed ID: 29247688
[TBL] [Abstract][Full Text] [Related]
19. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
[TBL] [Abstract][Full Text] [Related]
20. Rescue of ATXN3 neuronal toxicity in
Fardghassemi Y; Tauffenberger A; Gosselin S; Parker JA
Dis Model Mech; 2017 Dec; 10(12):1465-1480. PubMed ID: 29061563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
